IL-10-Mediated Refueling of Exhausted T Cell Mitochondria Boosts Anti-Tumour Immunity. by Ryan, Dylan & Frezza, Christian
 ij.hapres.com 
Immunometabolism. 2021;3(4):e210030. https://doi.org/10.20900/immunometab20210030 
Commentary 
IL-10-Mediated Refueling of Exhausted T Cell 
Mitochondria Boosts Anti-Tumour Immunity 
Dylan Ryan, Christian Frezza * 
MRC Cancer Unit, University of Cambridge, Cambridge Biomedical 
Campus, Cambridge CB2 0XZ, UK 
* Correspondence: Christian Frezza, Email: cf366@cam.ac.uk. 
ABSTRACT 
Immunotherapy has underscored a revolution in cancer treatment. Yet, 
many patients fail to respond due to T cell exhaustion. Here, an 
intervention that restores mitochondrial function reversed the exhausted 
T cell phenotype to promote cytotoxicity and durable anti-tumour 
responses in vivo. 
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Immunotherapy is a type of biological therapy that uses the bodys own 
immune system to treat cancer. It is often achieved by adoptive T cell 
transfer (ACT) and immune checkpoint blockades (ICBs), which 
preferentially target tumour-infiltrating lymphocytes (TILs), but fails to 
work in most patients. This failure is often attributed to the adoption of an 
“exhausted” T cell phenotype. Defining T cell exhaustion is complex, but 
the term primarily describes CD8+ effector T cells with a reduced capacity 
to secrete cytokines and elevated expression levels of inhibitory receptors 
[1]. In tumours, exhaustion of TILs can impair cytotoxic killing, which 
subsequently enables tumour progression. Two major subsets of 
exhausted CD8+ T cells include an ICB-responsive “progenitor exhausted” 
subset that can proliferate and differentiate into an ICB-unresponsive 
“terminally exhausted”. Nutrient restriction in the tumour 
microenvironment (TME) and impaired mitochondrial bioenergetics of 
TILs is a contributing factor to exhaustion and impaired anti-tumour 
killing. Writing in Nature Immunology, Guo et al. explored the possibility 
of reinvigorating terminally exhausted CD8+ T cells by combining a 
“metabolic intervention”, comprised of an IL-10-Fc fusion protein to 
restore mitochondrial fitness, in combination with ACT or ICB 
immunotherapy [2]. Their findings provide strong preclinical evidence 
that metabolic interventions can promote proliferation and cytotoxic 
activity of terminally exhausted effector T cells to enhance cancer 
immunotherapy. 
Interleukin-10 (IL-10) is a cytokine that can promote anti-tumor 
immunity. In this work, the authors first synthesized a recombinant fusion 
protein between human IL-10 and IgG1 (IL-10-Fc), which would cross-react 
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with the mouse IL-10 receptor and extend the half-life of the protein. To 
test the ability of IL-10-Fc to regulate T cell responses in vivo, the authors 
employed the poorly immunogenic B16F10 melanoma mouse model. They 
found that ACT of tumour antigen-specific PMEL CD8+ T cells with IL-10-Fc 
enhanced tumour infiltration of TILs and increased the number of CD8+ T 
cells with minimal impact on other lymphocytes or myeloid cells. 
Importantly, subset analysis revealed a specific expansion and improved 
effector functioning of terminally exhausted CD8+ T cells (PD1+TIM-3+ CD8+ 
T cells) in an IL-10 receptor-dependent manner. To confirm a direct effect 
of IL-10-Fc on terminally exhausted CD8+ T cells, independent of 
progenitor exhausted T cells, the authors first demonstrated an antigen-
specific increase in PD1+TIM-3+-double positive populations when they 
were co-administered with OT-I CD8+ T cells. Likewise, comparing the 
transfer of PD1+TIM-3−CD8+ (progenitor exhausted) and PD1+TIM-3+CD8+ 
(terminally exhausted) T cells confirmed a specific expansion of 
terminally exhausted T cells even in the absence of progenitor exhausted 
T cells. Finally, in vivo depletion of progenitors using diphtheria toxin (DT) 
and Tcf7DTR-GFP transgenic P14 T cells had no impact on the expansion and 
tumour-killing capacity of terminally exhausted T cells in B16-gp33 
tumours. These results show that IL-10-Fc can directly reinvigorate 
terminally exhausted CD8+ T cells and promote tumour killing via a 
progenitor-independent mechanism. 
IL-10 signaling is reported to oppose pro-inflammatory macrophage 
activation by antagonizing mTOR and promoting mitophagy [3]. Given the 
profound effect of IL-10 on macrophage metabolic reprogramming, the 
authors examined whether IL-10-Fc could elicit effects on the respiratory 
activity of CD8+ T cells. Using in vitro co-cultures of activated PMEL CD8+ T 
cells and B16F10 cancer cells, and ex vivo production of PD1+TIM-3+CD8+ T 
cells, respirometry analysis revealed an increase in oxygen consumption 
rates (OCR) upon treatment with IL-10-Fc. The increase in OCR was also 
accompanied by increased PMEL CD8+ T cell proliferation and cytotoxicity 
against B16F10 cells and was dependent on the IL-10 receptor. To 
determine whether the metabolic response was conserved between mouse 
and human T cells, the authors validated the ability of IL-10-Fc to increase 
respiration, proliferation and the cytotoxic activity of CAR-T cells targeting 
HER2-expressing cancer cells. These results clearly demonstrated that IL-
10-Fc could promote oxidative phosphorylation (OXPHOS) of mouse and 
human T cells and suggested that IL-10-Fc-induced metabolic 
reprogramming may underlie the enhanced proliferation and killing 
capacity in vitro.  
To explore the utility of using IL-10-Fc in vivo as an adjunct to cancer 
immunotherapy, Guo et al. utilized four different solid tumour models to 
assess safety and efficacy. Firstly, IL-10-Fc was shown to reduce B16F10 
tumour burden on its own and to synergize with ACT of PMEL CD8+ T cells. 
Secondly, ACT of OT-I CD8+ T cells with IL-10-Fc led to potent tumour 
regression in a large and established YUMM1.7-OVA melanoma model. 
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Thirdly, a combination of HER2-targeting CAR-T cells led to a 90% 
reduction in tumour size using the HER2-expressing MC38 model of colon 
adenocarcinoma. This finding was particularly notable as no pre-
conditioning was required for the robust anti-tumour activity of CAR-T 
cells. Overall, combination treatment of IL-10-Fc with ACT led to greater 
survival rates, and remarkably, sustained anti-tumour immune memory 
with many IL-10-Fc-treated mice surviving tumour re-challenge. Lastly, IL-
10-Fc was also found to synergize with anti-PD1 ICB immunotherapy in a 
mouse CT26 colorectal tumour model leading to tumour eradication and 
durable immune responses. These preclinical studies suggest that IL-10-Fc 
may successfully potentiate ACT and ICB immunotherapies with no overt 
toxicity. 
To mechanistically dissect how IL-10-Fc reinvigorated terminally 
exhausted CD8+ T cells in vivo, RNA sequencing (RNA-seq) analysis of 
PD1+TIM-3+CD8+ TILs from B16F10 tumours treated with either PBS or IL-
10-Fc was performed. Enrichment analysis revealed increases in genes 
relating to OXPHOS, effector T cell responses and a decrease in inhibitory 
receptor expression. PD1+TIM-3+CD8+ TILs isolated from tumours were 
also found to have elevated basal OCR and mitochondrial reactive oxygen 
species (mtROS) levels. To uncover a causal relationship between 
metabolic reprogramming and T cell reinvigoration, the authors took a 
pharmacological approach targeting key bioenergetic pathways, including 
glycolysis, glutaminolysis, and fatty acid oxidation (FAO). Here, the 
authors found an important role for glycolysis-derived pyruvate uptake 
into mitochondria via the mitochondrial pyruvate carrier (MPC) for the 
increase in IL-10-Fc-driven respiration and validated this using MPC-KO T 
cells. Furthermore, feeding OT-I CD8+ T cells with sodium pyruvate 
circumvented the need for IL-10-Fc and promoted PD1+TIM-3+CD8+ T cell 
proliferation. IL-10-Fc failed to promote expansion and anti-tumour 
cytotoxic activity of terminally exhausted CD8+ T cells in MPC-KO OT-I CD8+ 
T cells in both B16F10-OVA tumours and YUMM1.7-OVA tumours. These 
findings demonstrate that IL-10-Fc promotes OXPHOS and anti-tumour 
killing via a pyruvate and MPC-dependent refueling of mitochondria 
(Figure 1).  
While the involvement of mitochondrial pyruvate uptake and OXPHOS 
in reinvigorating terminally exhausted T cells is evident, precisely how IL-
10-Fc regulates MPC-dependent OXPHOS remains to be established. Given 
the known role of IL10-Fc in promoting mitophagy of damaged 
mitochondria [3], perhaps a similar mechanism is at play in terminally 
exhausted CD8+ T cells. In addition, improved mitochondrial fitness 
achieved by enforced peroxisome proliferator-activated receptor-gamma 
coactivator (PGC)--1α overexpression (and subsequently increased 
mitochondrial biogenesis) in CD8+ TILs improved anti-tumour efficacy in 
a mouse model of melanoma [4]. This work highlights the need to develop 
more therapeutic approaches that enhance mitochondrial fitness to 
improve T cell function and patient responses to immunotherapy. Since 
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pyruvate alone was sufficient to re-activate mitochondrial functions in 
exhausted CD8+ T cells, it is tempting to speculate that other dietary 
interventions could have similar effects, paving the way for diet-based 
immunomodulation. Whilst this work presents a very exciting 
development and compelling case for the combination of metabolic 
interventions and immunotherapies, it remains to be seen if these results 
will be applicable to a broad range of cancer types. The relevance of these 
findings to the clinic is also unclear as these experiment use highly 
immunogenic tumour antigens and involved a peritumoral mode of 
delivery for IL-10-Fc. Finally, a large gap still remains in the translation of 
preclinical mouse model therapies to the effective treatment of human 
disease. 
 
Figure 1. IL-10-Mediated Refueling of Exhausted T Cell Mitochondria Boosts Anti-Tumour Immunity. Figure 
created with Biorender.com. 
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